We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo ADLM 2026 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Multianalyte Quality Control Introduced for NAT Labs

By LabMedica International staff writers
Posted on 27 Apr 2009
A liquid stable, unassayed, multianalyte, third party quality control is available for nucleic acid testing (NAT) labs.

The product, called AmpliTrol III, was designed for use with qualitative in vitro diagnostic procedures for the detection of Human Immunodeficiency Virus, Type 1 (HIV-1), Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV) nucleic acids in human serum or plasma. The new configuration of AmpliTrol III has 60-day open-vial stability when stored at 2-8 ºC. Routine use provides laboratories with the means to monitor assay performance and assure quality on an ongoing basis.

Introduced by Bio-Rad (Hercules, CA, USA), AmpliTrol III is a full process positive control used in the same manner as a patient specimen to monitor sample preparation, amplification, and detection procedures. It is compatible with many commercially available NAT systems, including the Roche (Basel, Switzerland) Cobas AmpliScreen HIV-1 v1.5, Roche AmpliScreen HBV, Roche AmpliScreen HCV v2.0, and Chiron (Emeryville, CA, USA) Procleix HIV-1/HCV assays.

Bio-Rad Laboratories, Inc. is a manufacturer and distributor of life science clinical diagnostics and research products.

Related Links:

Bio-Rad
Roche
Chiron



Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Multi-Chamber Washer-Disinfector
WD 390

Latest Molecular Diagnostics News

Blood Test Reveals Hidden Pancreatic Cancer After Treatment
27 Apr 2009  |   Molecular Diagnostics

Gene Expression Test Refines Melanoma Biopsy Decision-Making
27 Apr 2009  |   Molecular Diagnostics

Genomic Assays Predict Anthracycline Benefit in Early-Stage Breast Cancer
27 Apr 2009  |   Molecular Diagnostics



ADLM